Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2023 Jun 1

PMID 37259344

Authors

Rachna M Kumar

Hitesh Kumar

Tanvi Bhatt

Rupshee Jain

Kanan Panchal

Akash Chaurasiya

Vikas Jain

Affiliations

Soon will be listed here.

Abstract

Cancer is one of the major causes of mortality, globally. Cancerous cells invade normal cells and metastasize to distant sites with the help of the lymphatic system. There are several mechanisms involved in the development and progression of cancer. Several treatment strategies including the use of phytoconstituents have evolved and been practiced for better therapeutic outcomes against cancer. Fisetin is one such naturally derived flavone that offers numerous pharmacological benefits, i.e., antioxidant, anti-inflammatory, antiangiogenic, and anticancer properties. It inhibits the rapid growth, invasiveness, and metastasis of tumors by hindering the multiplication of cancer cells, and prompts apoptosis by avoiding cell division related to actuation of caspase-9 and caspase-8. However, its poor bioavailability associated with its extreme hydrophobicity hampers its clinical utility. The issues related to fisetin delivery can be addressed by adapting to the developmental aspects of nanomedicines, such as formulating it into lipid or polymer-based systems, including nanocochleates and liposomes. This review aims to provide in-depth information regarding fisetin as a potential candidate for anticancer therapy, its properties and various formulation strategies.

Citing Articles

Fisetin as a chemoprotective and chemotherapeutic agent: mechanistic insights and future directions in cancer therapy.

Fatima R, Soni P, Sharma M, Prasher P, Kaverikana R, Mangalpady S Med Oncol. 2025; 42(4):104.

PMID: 40074915 DOI: 10.1007/s12032-025-02664-x.

Exploring the therapeutic promise of fisetin: molecular mechanisms and clinical aspects in lung cancer.

Goyal K, Babu M, Afzal M, Rekha A, Ali H, Gupta S J Complement Integr Med. 2025; .

PMID: 40013371 DOI: 10.1515/jcim-2024-0444.

Flavonoids and Flavonoid-Based Nanopharmaceuticals as Promising Therapeutic Strategies for Colorectal Cancer-An Updated Literature Review.

Smeu A, Marcovici I, Dehelean C, Dumitrel S, Borza C, Lighezan R Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006045 PMC: 11858883. DOI: 10.3390/ph18020231.

Targeting MUC1 with fisetin in oral squamous cell carcinoma.

Wang Q, Zhang H, Xiang S, Zhang L, Fan J, Xu Z Genes Dis. 2025; 12(3):101357.

PMID: 39926326 PMC: 11804558. DOI: 10.1016/j.gendis.2024.101357.

Rhus Verniciflua Stokes Inhibits PD-1 Expression and Induces Anticancer Effects by Enhancing T Cell Function.

Kim S, Lee Y, Lee W, Jong Moon H, Lee S Integr Cancer Ther. 2025; 24():15347354241308220.

PMID: 39760460 PMC: 11705362. DOI: 10.1177/15347354241308220.

References

Magne Nde C, Zingue S, Winter E, Creczynski-Pasa T, Michel T, Fernandez X . Flavonoids, Breast Cancer Chemopreventive and/or Chemotherapeutic Agents. Curr Med Chem. 2015; 22(30):3434 - 3446. View

Gothwal A, Khan I, Gupta U . Polymeric Micelles: Recent Advancements in the Delivery of Anticancer Drugs. Pharm Res. 2015; 33(1):18-39. DOI: 10.1007/s11095-015-1784-1. View

Kammerud S, Metge B, Elhamamsy A, Weeks S, AlSheikh H, Mattheyses A . Novel role of the dietary flavonoid fisetin in suppressing rRNA biogenesis. Lab Invest. 2021; 101(11):1439-1448. PMC: 8510891. DOI: 10.1038/s41374-021-00642-1. View

Chou R, Hsieh S, Yu Y, Huang M, Huang Y, Hsieh Y . Fisetin inhibits migration and invasion of human cervical cancer cells by down-regulating urokinase plasminogen activator expression through suppressing the p38 MAPK-dependent NF-κB signaling pathway. PLoS One. 2013; 8(8):e71983. PMC: 3733924. DOI: 10.1371/journal.pone.0071983. View

Jeong D, Choi J, Choi Y, Jeong K, Cho E, Jung S . Complexation of fisetin with novel cyclosophoroase dimer to improve solubility and bioavailability. Carbohydr Polym. 2013; 97(1):196-202. DOI: 10.1016/j.carbpol.2013.04.066. View

Xiao X, Zou J, Fang Y, Meng Y, Xiao C, Fu J . Fisetin and polymeric micelles encapsulating fisetin exhibit potent cytotoxic effects towards ovarian cancer cells. BMC Complement Altern Med. 2018; 18(1):91. PMC: 5855937. DOI: 10.1186/s12906-018-2127-7. View

Pawar A, Singh S, Rajalakshmi S, Shaikh K, Bothiraja C . Development of fisetin-loaded folate functionalized pluronic micelles for breast cancer targeting. Artif Cells Nanomed Biotechnol. 2018; 46(sup1):347-361. DOI: 10.1080/21691401.2018.1423991. View

Seguin J, Brulle L, Boyer R, Lu Y, Ramos Romano M, Touil Y . Liposomal encapsulation of the natural flavonoid fisetin improves bioavailability and antitumor efficacy. Int J Pharm. 2013; 444(1-2):146-54. DOI: 10.1016/j.ijpharm.2013.01.050. View

Zhang J, Jiang K, An K, Ren S, Xie X, Jin Y . Novel water-soluble fisetin/cyclodextrins inclusion complexes: Preparation, characterization, molecular docking and bioavailability. Carbohydr Res. 2015; 418:20-28. DOI: 10.1016/j.carres.2015.09.013. View

10.

Croy S, Kwon G . Polymeric micelles for drug delivery. Curr Pharm Des. 2006; 12(36):4669-84. DOI: 10.2174/138161206779026245. View

11.

Syed D, Adhami V, Imran Khan M, Mukhtar H . Inhibition of Akt/mTOR signaling by the dietary flavonoid fisetin. Anticancer Agents Med Chem. 2013; 13(7):995-1001. PMC: 3985520. DOI: 10.2174/18715206113139990129. View

12.

Adhami V, Syed D, Khan N, Mukhtar H . Dietary flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management. Biochem Pharmacol. 2012; 84(10):1277-81. PMC: 3813433. DOI: 10.1016/j.bcp.2012.07.012. View

13.

Abotaleb M, Samuel S, Varghese E, Varghese S, Kubatka P, Liskova A . Flavonoids in Cancer and Apoptosis. Cancers (Basel). 2019; 11(1). PMC: 6357032. DOI: 10.3390/cancers11010028. View

14.

Noh E, Park Y, Kim J, Kim M, Kim H, Song H . Fisetin regulates TPA-induced breast cell invasion by suppressing matrix metalloproteinase-9 activation via the PKC/ROS/MAPK pathways. Eur J Pharmacol. 2015; 764:79-86. DOI: 10.1016/j.ejphar.2015.06.038. View

15.

Moolakkadath T, Aqil M, Ahad A, Imam S, Praveen A, Sultana Y . Preparation and optimization of fisetin loaded glycerol based soft nanovesicles by Box-Behnken design. Int J Pharm. 2020; 578:119125. DOI: 10.1016/j.ijpharm.2020.119125. View

16.

Direito R, Reis C, Roque L, Goncalves M, Sanches-Silva A, Gaspar M . Phytosomes with Persimmon ( L.) Extract: Preparation and Preliminary Demonstration of In Vivo Tolerability. Pharmaceutics. 2019; 11(6). PMC: 6630258. DOI: 10.3390/pharmaceutics11060296. View

17.

Feng C, Yuan X, Chu K, Zhang H, Ji W, Rui M . Preparation and optimization of poly (lactic acid) nanoparticles loaded with fisetin to improve anti-cancer therapy. Int J Biol Macromol. 2018; 125:700-710. DOI: 10.1016/j.ijbiomac.2018.12.003. View

18.

Kimira M, Arai Y, Shimoi K, Watanabe S . Japanese intake of flavonoids and isoflavonoids from foods. J Epidemiol. 1998; 8(3):168-75. DOI: 10.2188/jea.8.168. View

19.

Lu H, Chang D, Baratte B, Meijer L, Schulze-Gahmen U . Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin. J Med Chem. 2005; 48(3):737-43. DOI: 10.1021/jm049353p. View

20.

Kang K, Piao M, Hyun J . Fisetin induces apoptosis in human nonsmall lung cancer cells via a mitochondria-mediated pathway. In Vitro Cell Dev Biol Anim. 2014; 51(3):300-9. DOI: 10.1007/s11626-014-9830-6. View